Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1/rhIGFBP-3 in Children With Growth Failure Due to Noonan Syndrome
NCT00351221Phase 2Terminated
- Sponsor
- Insmed Incorporated
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecasermin rinfabate in Noonan syndrome, sponsored by Insmed Incorporated. Primary endpoints: Pharmacokinetics, Safety and 1 more. Status: terminated.
02
Drugs
mecasermin rinfabate
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on NCT00351221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351221.